BiotechTube

HIL-214 + Placebo

Phase 2/3Terminated
0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroenteritis

Conditions

Gastroenteritis

Trial Timeline

Apr 28, 2022 → Sep 30, 2024

NCT ID
NCT05281094

About HIL-214 + Placebo

HIL-214 + Placebo is a phase 2/3 stage product being developed by HilleVax for Gastroenteritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05281094. Target conditions include Gastroenteritis.

What happened to similar drugs?

1 of 11 similar drugs in Gastroenteritis were approved

Approved (1) Terminated (1) Active (9)
✅Bacillus clausii + Oral Rehydration TherapySanofiApproved
🔄mRNA-1403ModernaPhase 3
❌Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)MerckPhase 3
🔄Rotavirus Vaccine, Live, Oral, PentavalentMerckPhase 3
🔄RotaTeq (V260) + IPVMerckPhase 3
🔄V260 + Placebo to V260 + OPV + DTaPMerckPhase 3
🔄Prulifloxacin + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
15
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05836012Phase 2/3Completed
NCT05281094Phase 2/3Terminated

Competing Products

20 competing products in Gastroenteritis

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
Placebo + HIL-214HilleVaxPhase 1
19
HIL-214 + PlaceboHilleVaxPhase 2/3
28
HIL-214HilleVaxPhase 2
25
Benralizumab + PlaceboAstraZenecaPhase 2/3
38
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)MerckPhase 3
32
Rotavirus VaccineMerckPre-clinical
18
Rotavirus Vaccine, Live, Oral, PentavalentMerckPhase 3
40
RotaTeq (V260) + IPVMerckPhase 3
40
V260 + Placebo to V260 + OPV + DTaPMerckPhase 3
40
Prulifloxacin + PlaceboMerckPhase 3
40
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: PlaceboMerckPhase 1
29
RotaTeq™ experimental formulation + RotaTeq™ existing formulationMerckPhase 3
40
prulifloxacinMerckPhase 3
40
montelukastMerckPre-clinical
26
Bacillus ClausiiSanofiPhase 3
40
Bacillus clausii + Oral Rehydration TherapySanofiApproved
43
VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine TabletVaxartPhase 1
19
VXA-G1.1-NN Oral VaccineVaxartPhase 1
19